Federation Des Caisses Desjardins Du Quebec Dia Medica Therapeutics Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.58 - $3.23 $593 - $742	230 New	230 $637,000
Q4 2020 Aug 30, 2024	BUY	$4.13 - $10.14 $949 - $2,332	230 Added 3.97%	6,030 $61.1 Million
Q4 2019 Aug 30, 2024	BUY	$1.8 - $5.04 $10,026 - $28,072	5,570 Added 2421.74%	5,800 $28.1 Million

Others Institutions Holding DMAC

# of Institutions

Shares Held

4.22M

Call Options Held

8.2K

Put Options Held

200

Vanguard Group Inc Valley Forge, PA

1.05M
Shares

$4.7 Million
0.0% of portfolio
First Manhattan CO New York, NY

839K
Shares

$3.76 Million
0.01% of portfolio
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX

483K
Shares

$2.16 Million
3.74% of portfolio
Bleichroeder LP New York, NY

382K
Shares

$1.71 Million
0.54% of portfolio
Geode Capital Management, LLC Boston, MA

307K
Shares

$1.38 Million
0.0% of portfolio

View Full List

About DiaMedica Therapeutics Inc.

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $118M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

More about DMAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account